Status:
UNKNOWN
Predictive Study of Serum Endocan for Hemorrhagic Transformation After Reperfusion Therapies in Acute Ischemic Stroke
Lead Sponsor:
Xijing Hospital
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Brief Summary
Stroke is the second largest cause of death globally after ischemic heart disease.Of the total number of prevalent strokes, 84.4% are ischemic. Reperfusion therapy is the most important treatment for ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute ischemic stroke and presentation at the hospital within 24h from symptom onset
- Eligibility for intravenous thrombolysis and/or endovascular treatment
- Age ≥18 years
Exclusion
- Administration of intravenous thrombolysis at another hospital in patients who are candidates for endovascular treatment
- Contraindications to intravenous thrombolysis
- Contraindications to iodinated contrast agent
- A history of ischemic stroke in three months
- Clinical diagnosis of autoimmune,inflammatory, hematological, or infectious diseases
- Clinical diagnosis of cancer
- Clinical diagnosis of severe cardiac,pulmonary,renal or liver failure
- Clinical diagnosis of dementia or psychosis
- Pregnant and lactating women
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05228080
Start Date
December 1 2021
End Date
February 1 2023
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, Shaanxi, China, 710032